NCT02099565View on ClinicalTrials.gov

Observational Prospective Study OPTIMA II - Follow-up

CompletedOBSERVATIONAL
Enrollment

572

Participants

Timeline

Start Date

May 31, 2014

Primary Completion Date

April 30, 2015

Study Completion Date

April 30, 2015

Conditions
Major Adverse Cardiovascular and Cerebrovascular Events (MACCE)
Trial Locations (1)

Unknown

Research Site, Moscow

Sponsors

Lead Sponsor

AstraZeneca
All Listed Sponsors
lead

AstraZeneca

INDUSTRY